What I’ve noticed, is work on extended release formulations only occur close to or near the time of patent expirations.
It’s rarely because of a new technological breakthrough, but rather a way of drug companies lengthening the time they can profit off a drug.
If they released it earlier they would simply take market share from themselves, but by releasing it close to the time of generics they take market share from generics.
Why didn’t Wegovy come out 5 years sooner? Why does it use a different injector than Ozempic? I don’t know but sounds quite similar to the ER/XR strategy.
It’s rarely because of a new technological breakthrough, but rather a way of drug companies lengthening the time they can profit off a drug.
If they released it earlier they would simply take market share from themselves, but by releasing it close to the time of generics they take market share from generics.
Why didn’t Wegovy come out 5 years sooner? Why does it use a different injector than Ozempic? I don’t know but sounds quite similar to the ER/XR strategy.